ISTH 2026: Incyte präsentiert Daten zur Mehrfachdosierung von VGA039 (Latarcibart) aus einer Phase-1/2-Studie, die eine deutliche Verringerung der Blutungen bei Patienten mit allen Formen des von-Willebrand-Syndroms zeigen
Tuesday, July 14, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Incyte has released complete safety and efficacy data from a Phase 1/2 study of VGA039 (Latarcibart), a monoclonal antibody targeting Protein S for von Willebrand syndrome (VWS) patients. The study involved 16 patients and demonstrated a notable reduction in bleeding events. These findings are being presented at the 34th Congress of the International Society on Thrombosis.
Price reaction · baseline $114.23 (2026-07-13 close) · hit pre-market · clean, no other INCY news in the window
day 0 close · peak
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Significant reduction in bleeding observed in patients.
Data presented at a reputable international congress.
Incyte's novel monoclonal antibody shows promise for VWS.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
INCB013739
Phase 2 · Type 2 Diabetes
Full Press Release Details
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) gab heute die vollständigen Sicherheits- und Wirksamkeitsdaten aller Patienten (n = 16) bekannt, die an der Phase-1/2-Studie zur Mehrfachdosierung von VGA039 (Latarcibart) teilnahmen. Latarcibart ist ein neuartiger, gegen Protein S gerichteter monoklonaler Antikörper in klinischer Prüfung für Patienten mit von-Willebrand-Syndrom (VWS). Die Daten werden heute im Rahmen eines Vortrags auf dem 34. Kongress der International Society on Thromb
Frequently Asked Questions
What is VGA039 used for?
VGA039 is a monoclonal antibody in clinical testing for von Willebrand syndrome.
How many patients were involved in the study?
The study included a total of 16 patients.
What were the results of the Phase 1/2 study?
The study showed a significant reduction in bleeding events among patients.
Where were the study results presented?
The results were presented at the 34th Congress of the International Society on Thrombosis.